
J&J exits the RSV vaccine development race with competitors Pfizer and GSK
March 30, 2023: On Wednesday, Johnson & Johnson said it’s ducking out of the RSV vaccine race, weeks following competitors Pfizer …
January 29, 2021: A new coronavirus vaccine known as Novavax, which is given in two doses, has shown 89.3% efficacy in large-scale UK trials.
The Novavax jab is the first to be effective in the trials against the new variant in the UK, the BBC’s medical editor Fergus Walsh said.
Prime Minister said the medicines regulator in the UK would now assess the vaccine.
The UK secured 60 million doses of the jab, which will be made in Stockton-on-Tees in north-east England.
The doses are expected to be delivered later this year if approved for use by the Medicines and Healthcare Products Regulatory Agency (MHRA), the government said.
The Phase 3 trials are looked at by a regulator, enrolled more than 15,000 people aged 18 to 84, and 27% were older than 65, US firm Novavax said.
Chief executive of Novavax, Stan Erck, said the UK trial results were “spectacular” and “as good as we could have hoped.” At the same time, the efficacy in South Africa was above the people’s expectations.
Health Secretary Matt Hancock said the Novavax vaccine would be “another weapon in our arsenal to beat this awful virus” if approved.
Hancock thanked researches and volunteers for taking part in the trials, “I’m proud the UK is at the forefront of another medical breakthrough,” he said.
According to the UK Novavax trial’s chief investigator, the clinical trial findings were enormously exciting because of the jab’s efficacy against the new variant of the disease.
Peter Openshaw, professor at Imperial College in London, said the findings that the vaccine gave high levels of protection in the UK part of the trial were “excellent” but that the lower level of protection seen in South Africa was “a concern.”
We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.
March 30, 2023: On Wednesday, Johnson & Johnson said it’s ducking out of the RSV vaccine race, weeks following competitors Pfizer …
March 30, 2023: On Wednesday, Ovo Energy plans to seize Shell Plc’s UK gas and electricity business. Sky News reported that …
March 30, 2023: On Wednesday, Bitcoin ascended as investors shrugged off initial fears about what is surrounding U.S. regulators’ crackdowns …
Trōv is a global leader in embedded insurance, powering the future of digital insurance distribution and emerging mobility. Its robust insurtech platform empowers financial institutions and insurance incumbents to easily embed insurance products within other digital experiences to increase recurring revenue.
While only one in ten homes throughout the United States has flood insurance coverage, floods are the country’s most common and deadli-est natural disaster. Since 2000, they have cost American taxpayers $850 billion, two-thirds of the total cost of all natural disasters, yet only 1 out of 10 homes are insured for flood, and that number could soon be reduced.
Insurance needs to be more precise as there are solutions that protect the assets owned by the Property Managers (apartment units) and solutions that protect the Residents and their personal belongings. Which programs to offer and buy depends on each unique client’s needs.